MaxCyte, Inc. Common Stock (MXCT) Stock Price
MXCTStock
$1.30−26.55%52W
Market Cap$134.17M
P/E—
PEG Ratio—
Div yield—
Beta1.53
MXCT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)37.65%
Price vs S&P 500 (4W)7.88%
VGM Score44.47
MXCT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.09 | -$0.08 | +14.28%(+$0.01) | |
| Q4 2025 | -$0.08 | -$0.06 | +32.08%(+$0.03) | |
| Q3 2025 | -$0.10 | -$0.09 | +12.22%(+$0.01) | |
| Q2 2025 | -$0.10 | -$0.12 | -17.65%(-$0.02) |
MXCT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.15
4.15
4.25
4.25
Industry Peers — R&D — Physical Sciences(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
MXCTMaxCyte, Inc. Common Stock | C | D | B | — | -21.0% | 4.8% | — | $1.30 |
| IQVIQVIA Holdings Inc. | D | C | A | 32.3x | 21.9% | 7.5% | — | $266.90 |
| INCYIncyte Genomics Inc | C | B | B | 17.8x | 29.6% | 14.0% | — | $113.07 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | 38.3x | 110.2% | 22.3% | — | $618.47 |
| CRLCharles River Laboratories International, Inc. | F | D | A | — | -7.7% | 6.5% | — | $300.15 |
| ICLRIcon Plc | C | C | B | 57.3x | 0.8% | 24.1% | — | $170.18 |
| ABSIAbsci Corporation Common Stock | F | F | B | — | -59.2% | -10.1% | — | $8.25 |
| OABIOmniAb, Inc. Common Stock | F | B | A | — | -16.6% | -4.3% | — | $4.59 |
| NRCNRC Health Common Stock | D | D | B | 38.4x | 48.5% | 0.6% | 1.2% | $20.15 |
| IBACIB Acquisition Corp. Common Stock | — | D | C | 15.9x | -3.7% | — | — | $10.86 |
| ONMDOneMedNet Corp Class A Common Stock | D | A | D | — | -6.8% | — | — | $4.51 |
About MaxCyte, Inc. Common Stock
MaxCyte Inc is a commercial cell engineering company that develops and commercializes technologies for the discovery and development of next-generation cell therapeutics. The company's proprietary Flow Electroporation platform enables the efficient engineering of diverse cell types for therapeutic and research applications. MaxCyte generates revenue from the sale and licensing of its instruments and related single-use disposable processing assemblies.